Phase 1b Escalating Study to Evaluate the Safety and Immunogenicity of Recombinant Ricin Toxin A-Chain 1-33/44-198 (rRTA 1-33/44-198) Vaccine (RVEc) Administered Intramuscularly to Healthy Adults as a 3-Dose Primary Series and Booster

Trial Profile

Phase 1b Escalating Study to Evaluate the Safety and Immunogenicity of Recombinant Ricin Toxin A-Chain 1-33/44-198 (rRTA 1-33/44-198) Vaccine (RVEc) Administered Intramuscularly to Healthy Adults as a 3-Dose Primary Series and Booster

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 04 Mar 2017

At a glance

  • Drugs Ricin vaccine (Primary)
  • Indications Ricin poisoning
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Feb 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 24 Nov 2015 Planned initiation date changed from 1 Oct 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov record.
    • 03 May 2015 Planned initiation date changed from 1 May 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top